HC
REGN icon

Hurley Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Hurley Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$1.13K – 724
2025
Q3 		$1.13K Sell
2
-13
-87% -$7.35K ﹤0.01% 534
2025
Q2 		$7.88K Hold
15
– – 0.01% 333
2025
Q1 		$9.51K Buy
+15
New +$10.3K 0.01% 324

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Hurley Capital's REGN Position: Q4 2025 in Review

Hurley Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 2 shares — an estimated $1.13K sold.

Hurley Capital first reported a position in REGN in Q1 2025 and held it in 3 quarters. The position peaked at $9.51K in Q1 2025. 1,387 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Hurley Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Hurley Capital sold 2 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $1.13K.
  • Hurley Capital first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Hurley Capital's Regeneron Pharmaceuticals position peaked at $9.51K in Q1 2025.
  • 1,387 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Hurley Capital's 13F filing for Q4 2025, filed 17 Feb 2026.